Publications by authors named "G Fallara"
Background: Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic.
Objective: We provide a systematic review and meta-analysis of trials to assess efficacy of immune checkpoint inhibitors (ICI) combined with antiangiogenic agents in UC.
Methods: Following PRISMA guidelines, we searched for trials with at least one arm of patients with UC treated with ICI plus antiangiogenics.
Introduction: Kidney transplant (KT) recipients are at an elevated risk of developing de novo cancers. However, penile (PeCa) and testis cancers have received limited attention in this setting.
Objective: To summarize the epidemiology, treatment options, and oncological outcomes of penile and testis cancer in KT recipients.
Objectives: Survival outcomes of patients with metastatic urothelial carcinoma (mUC) are still suboptimal and strategies to enhance response to immune-oncology (IO) compounds are under scrutiny. In preclinical studies, it has been demonstrated that antihistamines may reverse macrophage immunosuppression, reactivate T cell cytotoxicity, and enhance the immunotherapy response. We aimed to evaluate the role of concomitant antihistamines administration on oncological outcomes among patients with mUC.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the impact of smoking on the outcomes of nonmuscle invasive bladder cancer (NMIBC) treated with BCG instillations, indicating that smokers may have poorer results.
- Approximately 1,313 patients were analyzed using a statistical model to correlate smoking history with disease progression, revealing that heavy smokers have over double the risk of disease progression compared to nonsmokers.
- The results highlight the importance of considering a patient's smoking history in NMIBC management and the necessity for tailored smoking cessation strategies in treatment plans.
Article Synopsis
- - The study investigates the expression of nectin-4 (N4) in various genitourinary (GU) cancers, particularly focusing on its relevance as a potential target for antibody-drug conjugates, given its aberrant expression in malignancies like urothelial carcinoma of the bladder (UBC).
- - A systematic review analyzed 25 studies on N4 positivity across different GU tumors, finding that N4 positivity is generally higher in bladder cancers, especially in metastatic and non-muscle-invasive stages, compared to other types like upper tract urothelial carcinoma and non-urothelial cancers.
- - The findings suggest that non-urothelial malignancies have lower rates of N4 positivity compared to bladder cancer,